Archives of Gynecology and Obstetrics

, Volume 298, Issue 4, pp 747–753 | Cite as

Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice

  • Thomas RömerEmail author
General Gynecology



Endometriosis is a debilitating disease with high recurrence rates requiring long-term management. Progestins such as dienogest are used empirically when first symptoms occur and post-surgery to reduce recurrence. This retrospective, practice-based study assessed the efficacy and safety of dienogest in women with endometriosis treated for at least 60 months.


37 women (age 39 ± 8 years) with laparoscopically diagnosed endometriosis received dienogest 2 mg orally once daily. Endometriosis-associated pelvic pain (EAPP) was measured on a 0–100 mm visual analog scale at baseline and every 12 months. Laboratory measures of lipid and liver metabolism, hemostatic and hormonal parameters were investigated in a subgroup of 15 women. Adverse events including bleeding disturbances and depressive symptoms were recorded.


In 22 women, dienogest was begun after laparoscopy; median EAPP score was 70 mm pre-surgery and 10, 10, 20, 20, and 20 mm, respectively, after 12, 24, 36, 48, and 60 months of dienogest treatment. Another 15 women began dienogest without prior surgery; median EAPP score was 80 mm pretreatment and 20, 20, 30, 30, and 30 mm, respectively, after 12, 24, 36, 48, and 60 months. All laboratory parameters remained within the normal range. Mean serum estradiol was 28 ± 12 pg/ml after 60 months. Seven women experienced spotting episodes and four women presented with phases of depressed mood, which could all be clinically managed.


Long-term (60-month) treatment with dienogest 2 mg once-daily in women with endometriosis effectively reduced EAPP and avoided pain recurrence post-surgery. Dienogest was well tolerated and adverse effects were clinically managed.


Dienogest Endometriosis Long-term management 



Editorial assistance was provided by Bill Wolvey of PAREXEL International, which was contracted by Bayer AG.

Author contributions

TR participated in the project development, data collection and management, data analysis, and manuscript editing.


No study funding was received.

Compliance with ethical standards

Conflict of interest

Prof. Römer has received honoraria for lectures and advisory boards from: Bayer, MSD, Gedeon Richter, Dr. KADE, and Aristo Pharma.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ (1991) Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 55(4):759–765CrossRefGoogle Scholar
  2. 2.
    Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, Stratton P (2008) Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril 89(3):538–545. CrossRefPubMedGoogle Scholar
  3. 3.
    Soliman AM, Coyne KS, Zaiser E, Castelli-Haley J, Fuldeore MJ (2017) The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study. J Psychosom Obstet Gynaecol 38(4):238–248. CrossRefPubMedGoogle Scholar
  4. 4.
    Guo SW (2009) Recurrence of endometriosis and its control. Hum Reprod Update 15(4):441–461. CrossRefPubMedGoogle Scholar
  5. 5.
    Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W, European Society of Human Reproduction and Embryology (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29(3):400–412. CrossRefPubMedGoogle Scholar
  6. 6.
    Falcone T, Lebovic DI (2011) Clinical management of endometriosis. Obstet Gynecol 118(3):691–705. CrossRefPubMedGoogle Scholar
  7. 7.
    Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier Consortium (2013) Consensus on current management of endometriosis. Hum Reprod 28(6):1552–1568. CrossRefPubMedGoogle Scholar
  8. 8.
    Kuznetsov L, Dworzynski K, Davies M, Overton C, Committee Guideline (2017) Diagnosis and management of endometriosis: summary of NICE guidance. BMJ 358:j3935. CrossRefPubMedGoogle Scholar
  9. 9.
    Leyland N, Casper R, Laberge P, Singh SS, SOCG (2010) Endometriosis: diagnosis and management. J Obstet Gynaecol Can 32(7 Suppl 2):S1–S32CrossRefGoogle Scholar
  10. 10.
    Practice Committee of the American Society for Reproductive Medicine (2014) Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 101(4):927–935. CrossRefGoogle Scholar
  11. 11.
    Angioni S, Cofelice V, Pontis A, Tinelli R, Socolov R (2014) New trends of progestins treatment of endometriosis. Gynecol Endocrinol 30(11):769–773. CrossRefPubMedGoogle Scholar
  12. 12.
    Brown J, Kives S, Akhtar M (2012) Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 3:CD002122. CrossRefGoogle Scholar
  13. 13.
    Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B (2016) Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res 65(3):183–192. CrossRefPubMedGoogle Scholar
  14. 14.
    Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N (2005) Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 83(5):1530–1535. CrossRefPubMedGoogle Scholar
  15. 15.
    Katsuki Y, Takano Y, Futamura Y, Shibutani Y, Aoki D, Udagawa Y, Nozawa S (1998) Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 138(2):216–226CrossRefGoogle Scholar
  16. 16.
    Mita S, Shimizu Y, Notsu T, Imada K, Kyo S (2011) Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil Steril 96(6):1485–1489 e1484. CrossRefPubMedGoogle Scholar
  17. 17.
    Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y (2014) Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 30(9):644–648. CrossRefPubMedGoogle Scholar
  18. 18.
    Nirgianakis K, Grandi G, McKinnon B, Bersinger N, Cagnacci A, Mueller M (2016) Dienogest mediates midkine suppression in endometriosis. Hum Reprod 31(9):1981–1986. CrossRefPubMedGoogle Scholar
  19. 19.
    Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, Terakawa N (2009) Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91(3):675–681. CrossRefPubMedGoogle Scholar
  20. 20.
    Kohler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 108(1):21–25. CrossRefPubMedGoogle Scholar
  21. 21.
    Strowitzki T, Faustmann T, Gerlinger C, Seitz C (2010) Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 151(2):193–198. CrossRefPubMedGoogle Scholar
  22. 22.
    Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25(3):633–641. CrossRefPubMedGoogle Scholar
  23. 23.
    Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2012) Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet 117(3):228–233. CrossRefPubMedGoogle Scholar
  24. 24.
    Morotti M, Sozzi F, Remorgida V, Venturini PL, Ferrero S (2014) Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol 183:188–192. CrossRefPubMedGoogle Scholar
  25. 25.
    Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, Somigliana E (2016) Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 105(3):734–743 e733. CrossRefPubMedGoogle Scholar
  26. 26.
    Momoeda M, Harada T, Terakawa N, Aso T, Fukunaga M, Hagino H, Taketani Y (2009) Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 35(6):1069–1076. CrossRefPubMedGoogle Scholar
  27. 27.
    Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, Lazzeri L, Strowitzki T (2012) Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 285(1):167–173. CrossRefPubMedGoogle Scholar
  28. 28.
    Schindler AE (2011) Dienogest in long-term treatment of endometriosis. Int J Womens Health 3:175–184. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H (2016) Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet Gynecol Sci 59(6):506–511. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA (2017) Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol 211:108–111. CrossRefPubMedGoogle Scholar
  31. 31.
    Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, Alio L (2017) Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch Gynecol Obstet. CrossRefPubMedGoogle Scholar
  32. 32.
    Park SY, Kim SH, Chae HD, Kim CH, Kang BM (2016) Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med 43(4):215–220. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lang J, Yu Q, Zhang S, Li H, Gude K, von Ludwig C, Ren X, Dong L (2017) Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Womens Health (Larchmt). CrossRefGoogle Scholar
  34. 34.
    Ota Y, Andou M, Yanai S, Nakajima S, Fukuda M, Mi Takano, Kurotsuchi S, Ebisawa K, Hada T, Ota I (2015) Long-term administration of dienogest reduces recurrence after excision of endometrioma. J Endometr Pelvic Pain Disord 7(2):63–67. CrossRefGoogle Scholar
  35. 35.
    Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M (2017) Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol 216:51–55. CrossRefPubMedGoogle Scholar
  36. 36.
    Strowitzki T, Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C (2015) Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health 7:393–401. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Revised American society for reproductive medicine classification of endometriosis: 1996 (1997). Fertil Steril 67(5):817–821Google Scholar
  38. 38.
    Visanne [prescribing information] (2016) Bayer AG: Leverkusen, Germany. Available at:
  39. 39.
    Lang J, Zhang X, Zhou Y, Di W, Gude K, Dong L (2017) Efficacy and safety of dienogest in Chinese women with endometriosis: a 24-week, multicenter, randomized, placebo-controlled study with 28-week open-label phase. Presented at the 13th World Congress on Endometriosis, Vancouver, Canada, 17–20 May 2017Google Scholar
  40. 40.
    Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C (2010) Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes 8:138. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG (2003) Progestogens for endometriosis: forward to the past. Hum Reprod Update 9(4):387–396CrossRefGoogle Scholar
  42. 42.
    Sepulcri Rde P, do Amaral VF (2009) Depressive symptoms, anxiety, and quality of life in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 142(1):53–56. CrossRefPubMedGoogle Scholar
  43. 43.
    Lorencatto C, Petta CA, Navarro MJ, Bahamondes L, Matos A (2006) Depression in women with endometriosis with and without chronic pelvic pain. Acta Obstet Gynecol Scand 85(1):88–92CrossRefGoogle Scholar
  44. 44.
    Fuldeore MJ, Soliman AM (2017) Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Invest 82(5):453–461. CrossRefPubMedGoogle Scholar
  45. 45.
    Vitale SG, Petrosino B, La Rosa VL, Rapisarda AM, Lagana AS (2016) A systematic review of the association between psychiatric disturbances and endometriosis. J Obstet Gynaecol Can 38(12):1079–1080. CrossRefPubMedGoogle Scholar
  46. 46.
    Barbieri RL (1992) Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 166(2):740–745CrossRefGoogle Scholar
  47. 47.
    Lee DY, Park HG, Yoon BK, Choi D (2016) Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis. Obstet Gynecol Sci 59(1):32–38. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Obstetrics and Gynecology Department, Academic Hospital WeyertalUniversity of CologneCologneGermany

Personalised recommendations